Psyence Group’s NASDAQ-Listed Affiliate, Psyence Biomedical, Additional Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Article content material

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Firm“) (CSE: PSYG) is happy that its NASDAQ-listed affiliate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed“), has introduced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a acknowledged chief within the area of psychopharmacology.

Article content material

Article content material

In keeping with a information launch issued by PBM, Dr. Stein is the Professor and Chair of the Dept of Psychiatry and Psychological Well being on the College of Cape City (UCT) and Director of the South African Medical Analysis Council (MRC) Unit on Threat & Resilience in Psychological Issues. Dr. Stein will work carefully with SAB chairman, Albert P. Garcia-Romeu, Ph.D, an Affiliate Professor within the Division of Psychiatry and Behavioral Sciences, Johns Hopkins College College of Medication. The PBM information launch goes on to state that along with the continuation of PBM’s Part IIb scientific trial of psilocybin as a possible remedy for Adjustment Dysfunction in Palliative Care, PBM may also be advancing plans for its second improvement indication in Alcohol Use Dysfunction, introducing a wholly new class of psilocybin-based therapeutics to handle vital unmet wants in psychological well being and habit.

Article content material

PBM will focus on the position of the SAB in a company webinar scheduled for Thursday, April 10, 2025, at 12:00 p.m. EST, throughout which the manager crew may also focus on PBM’s broader imaginative and prescient for the way forward for psychedelic therapeutics.

To register for the company webinar, please entry the next hyperlink: Psyence Biomed Company Webinar

The Firm has granted an combination of 9,034,487 restricted share models (every an “RSU“) to sure executives, officers, administrators and consultants of the Firm pursuant to the Firm’s RSU Plan, of which one third vests on the grant date, one other one third after 12 months and the remaining stability after 24 months. All RSUs expire December 31, 2030. Every RSU represents the fitting to obtain, as soon as vested, one frequent share within the capital of the Firm for each RSU held.

About Psyence Group and Psyence Biomed:

Psyence Group is a life science biotechnology firm listed on the Canadian Securities Alternate (CSE: PSYG), with a give attention to pure psychedelics. Psyence Biomed is the world’s first life science biotechnology firm traded on the Nasdaq (NASDAQ: PBM) that’s targeted on the event of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines, and works with pure psilocybin merchandise for the therapeutic of psychological trauma and its psychological well being penalties within the context of palliative care. Our identify “Psyence” combines the phrases psychedelic and science to affirm our dedication to producing psychedelic medicines developed via evidence-based analysis.

Article content material

Article content material

Knowledgeable by nature and guided by science, Psyence Group works to develop superior pure psilocybin merchandise for scientific analysis and improvement.

Study extra at www.psyence.com.

Study extra at www.psyencebiomed.com and on LinkedIn.

Contact Info for Psyence Group
E-mail: ir@psyence.com
Media Inquiries: media@psyence.com
Basic Info: information@psyence.com
Telephone: +1 416-477-1708

Contact Info for Psyence Biomed
E-mail: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
Basic Info: information@psyencebiomed.com
Telephone: +1 416-477-1708

Investor Contact:
Michael Kydd
Investor Relations Advisor michael@psyencebiomed.com

Ahead Wanting Statements

This communication accommodates “forward-looking statements” throughout the which means of relevant securities laws. Such statements embody, however are usually not restricted to, statements about expectations and intentions with respect to future operations, services; and different statements recognized by phrases similar to “will possible consequence,” “are anticipated to,” “will proceed,” “is anticipated,” “estimated,” “consider,” “intend,” “plan,” “projection,” “outlook” or phrases of comparable which means.

Article content material

Ahead-looking statements on this communication embody statements concerning the continuation of PBM’s Pallicybin Part IIb scientific trial and the pursuit of a second indication. These forward-looking statements are primarily based on quite a few assumptions, together with the belief that there is not going to be any delays within the execution of PBM’s Pallicybin Part IIb scientific trial and that PBM could have ample assets to pursue a second indication.

There are quite a few dangers and uncertainties which will trigger precise outcomes or efficiency to be materially completely different from these expressed or implied by these forward-looking statements. These dangers and uncertainties embody, amongst others: (i) delays within the registration of the Psyence Biomed frequent shares (ii) the power of Psyence Biomed to keep up the itemizing of its frequent shares and warrants on Nasdaq; and (v) volatility within the value of the securities of Psyence Biomed attributable to a wide range of elements, together with modifications within the aggressive and extremely regulated industries by which Psyence Biomed operates, variations in efficiency throughout rivals, modifications in legal guidelines and laws affecting Psyence Biomed’s enterprise and modifications in Psyence Biomed’s capital construction. The foregoing checklist of things will not be exhaustive. You must rigorously contemplate the foregoing elements and the opposite dangers and uncertainties described within the “Threat Components” part of the of the Firm’s administration dialogue and evaluation filed on sedarplus.com, and in PBM’s closing prospectus (File No. 333-284444) filed with the Securities and Alternate Fee (the “SEC“) on January 24, 2025 and different paperwork filed by PBM infrequently with the SEC. These filings determine and deal with different essential dangers and uncertainties that might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Precise outcomes and future occasions might differ materially from these anticipated in such data. Nothing on this communication must be considered a illustration by any person who the forward-looking statements set forth herein will probably be achieved or that any of the contemplated outcomes of such forward-looking statements will probably be achieved. You shouldn’t place undue reliance on forward-looking statements, which communicate solely as of the date they’re made. Besides as required by legislation, neither Psyence Group nor PBM intends to replace these forward-looking statements.

Article content material

The Firm makes no medical, remedy or well being profit claims in regards to the Firm’s proposed merchandise. The U.S. Meals and Drug Administration, Well being Canada or different related regulatory authorities haven’t evaluated claims concerning psilocybin, psilocybin analogues, or different psychedelic compounds or nutraceutical merchandise. The efficacy of such merchandise has not been confirmed by accepted analysis. There is no such thing as a assurance that using psilocybin, psilocybin analogues, or different psychedelic compounds or nutraceuticals can diagnose, deal with, remedy or stop any illness or situation. Vigorous scientific analysis and scientific trials are wanted. The Firm has not performed scientific trials for using its proposed merchandise. Any references to high quality, consistency, efficacy, and security of potential merchandise don’t indicate that the Firm verified such in scientific trials or that the Firm will full such trials. If the Firm can’t receive the approvals or analysis essential to commercialize its enterprise, it might have a cloth antagonistic impact on the Firm’s efficiency and operations.

Article content material